Industry News
Pharmaceutical Industry News
Arcutis reups ahead of critical year for topical drug delivery tech, securing $225M debt financing to fund product launch, pivotal readouts
Arcutis reups ahead of critical year for topical drug delivery tech, securing $225M debt financing to fund product launch, pivotal readouts ntaylor Tue, 01/04/2022 - 06:39
GSK targets the future of multiple myeloma with new think tank challenge
GSK targets the future of multiple myeloma with new think tank challenge badams Tue, 01/04/2022 - 03:39
EyeD lands $51M to take glaucoma implant into the clinic
EyeD lands $51M to take glaucoma implant into the clinic ntaylor Mon, 01/03/2022 - 09:51
SanPlena sets out to show wearable patches are the key to faster weight loss
SanPlena sets out to show wearable patches are the key to faster weight loss ntaylor Mon, 01/03/2022 - 09:48
Oravax inks oral COVID-19 vaccine supply deal amid talks about public listing
Oravax inks oral COVID-19 vaccine supply deal amid talks about public listing ntaylor Mon, 01/03/2022 - 09:44
MassBio report highlights racial disparities in biopharma workforce, improvement in gender diversity on boards
MassBio report highlights racial disparities in biopharma workforce, improvement in gender diversity on boards nmissakian Fri, 12/31/2021 - 20:53
Racial disparities continue to plague biopharma workforce, report finds—but boards do have more women
Racial disparities continue to plague biopharma workforce, report finds—but boards do have more women nmissakian Fri, 12/31/2021 - 20:53
Alzheimer’s Drug Aduhelm Faces Crucial Medicare Decision
Medicare officials are trying to determine whether to cover Aduhelm, which the F.D.A. approved despite unclear evidence that it helps patients.
Despite advances, HIV stigma and misunderstanding remain, GSK and ViiV study shows
Despite advances, HIV stigma and misunderstanding remain, GSK and ViiV study shows sharon.coey Fri, 12/31/2021 - 11:34
F.D.A. Plans to Allow 12- to 15-Year-Olds to Receive Pfizer Boosters
Regulators are also expected to allow even younger children with immune deficiencies to get an extra shot.
Teva Pharmaceuticals Found Liable in Landmark Opioid Trial
The case was the first of its kind, targeting every point of the prescription opioid supply chain, from manufacturers to pharmacy chains that filled prescriptions.
Xeris Biopharma scores FDA approval for endogenous Cushing’s syndrome drug Recorlev
Xeris Biopharma scores FDA approval for endogenous Cushing's syndrome drug Recorlev esagonowsky Thu, 12/30/2021 - 17:26
Teva suffers trial loss in New York’s landmark opioid case
Teva suffers trial loss in New York's landmark opioid case esagonowsky Thu, 12/30/2021 - 14:51
To buy or not to buy? Samsung unit denies report about Biogen talks
To buy or not to buy? Samsung unit denies report about Biogen talks esagonowsky Thu, 12/30/2021 - 08:13
J. & J. Booster Protects Against Severe Omicron, Study Says
Two shots of the vaccine reduced the risk of hospitalization from the fast-spreading variant by 85 percent, a clinical trial found.
Don’t spam us, healthcare professionals plea, as they seek quality over quantity from pharma marketers
Don't spam us, healthcare professionals plea, as they seek quality over quantity from pharma marketers nmissakian Wed, 12/29/2021 - 17:29
Biogen’s rollercoaster 2021 takes another surprising turn with report of $42B Samsung buyout interest
Biogen's rollercoaster 2021 takes another surprising turn with report of $42B Samsung buyout interest qanderson Wed, 12/29/2021 - 15:13
Biogen’s roller coaster 2021 takes another surprising turn with report of $42B Samsung buyout interest
Biogen's roller coaster 2021 takes another surprising turn with report of $42B Samsung buyout interest qanderson Wed, 12/29/2021 - 15:13
Bristol Myers Squibb, Amgen and Pfizer approach steepest patent cliffs among large drugmakers
Bristol Myers Squibb, Amgen and Pfizer approach steepest patent cliffs among large drugmakers aliu Wed, 12/29/2021 - 10:04
Leo Pharma gains FDA nod for eczema drug Adbry, but can it challenge Sanofi and Regeneron’s formidable Dupixent?
Leo Pharma gains FDA nod for eczema drug Adbry, but can it challenge Sanofi and Regeneron's formidable Dupixent? kdunleavy Tue, 12/28/2021 - 11:09